Obtaining a Natural Product Number (NPN) in Canada typically takes approximately 60 calendar days for Class I applications, 90 calendar days for Class II applications, and 270 or more calendar days for Class III applications. Due to current review backlogs, companies submitting Class III applications should plan for timelines closer to one year and ensure that Canadian manufacturing, sales, and active site licence information are accurately disclosed to support Health Canada’s workload prioritization efforts. Source Nutraceutical, Inc. (SNI) supports companies throughout the NPN process, from product classification and application preparation to submission strategy and regulatory support.
Introduction
A product label may be almost finalized, inventory may be ready, and a retailer may already be asking for a launch date. However, if a natural health product (NHP) does not yet have a Natural Product Number (NPN), it cannot legally be sold in Canada.
Health Canada’s current NHP review timelines are:
- 60 calendar days for Class I applications
- 90 calendar days for Class II applications
- 270 or more calendar days for Class III applications
These service standards include administrative screening, regulatory screening, and, where applicable, scientific assessment. They are not guaranteed approval dates. Actual processing times depend on the application class, the quality and completeness of the submission, Health Canada’s workload, and whether the Natural and Non-prescription Health Products Directorate (NNHPD) requests additional information.
For Class III applications in particular, brands should plan conservatively. Based on Source Nutraceutical, Inc.’s (SNI’s) experience with the current Health Canada application backlog, applicants should consider building approximately one year into their commercialization plan, especially for complex formulations, non-monograph claims, novel evidence packages, or submissions that may trigger an Information Request Notice (IRN).
Protecting the Canadian launch timeline begins well before the application is submitted. Brands must select the correct regulatory pathway, prepare a complete and internally consistent PLA, accurately complete the applicable sales and manufacturing attestations, and align the evidence, quality documentation, site information, and Canadian label.
What Determines the NPN Application Timeline?
Health Canada classifies NHP applications according to the extent to which the product complies with the Directorate’s pre-cleared monographs and whether independent evidence or scientific assessment is required.
Class I NPN Applications: 60 Calendar Days
A Class I application must fully comply with all parameters of a single Health Canada monograph. This includes the medicinal ingredients, source materials, doses, dosage form, route of administration, recommended uses, target population, directions, duration of use, and risk information.
The electronic PLA form validates much of the submitted information against the selected monograph. If a validated parameter falls outside the monograph, the form may prevent the applicant from finalizing the application as Class I.
Although Class I is the shortest licensing pathway, the 60-day service standard does not compensate for an inaccurate classification or incomplete submission. Ingredient names, source materials, non-medicinal ingredients, label text, and company information must still be accurate and internally consistent.
Class II NPN Applications: 90 Calendar Days
Class II applications typically rely on one or more Health Canada monographs but require additional regulatory screening because of the product’s formulation, combination of ingredients, claims, or conditions of use.
Applicants must identify all applicable monographs in the PLA. Health Canada then verifies the application against the selected monograph parameters and assesses any permissible deviations or combination considerations.
The 90-day service standard should be treated as a review target rather than a guaranteed licensing date. Incorrect monograph attestations, missing label text, unsupported conditions of use, or inconsistencies between the PLA and supporting documents can result in an IRN or refusal.
Class III NPN Applications: 270 or More Calendar Days
Class III applications require a more comprehensive scientific and regulatory assessment. This pathway generally applies when one or more elements of the product are not fully supported by Health Canada’s pre-cleared monographs.
A Class III application may be required where:
- A medicinal ingredient is not covered by an applicable monograph
- A proposed claim falls outside established monograph wording
- The proposed dose or route of administration is not monograph-aligned
- A required condition of use is omitted or modified
- Product-specific safety or efficacy evidence is required
- A scientific rationale or Master File information is needed
- The formulation involves complex combinations or novel technologies
For every parameter that is not supported by a monograph, the applicant must provide appropriate evidence or a scientifically defensible rationale. Health Canada also strongly encourages applicants to include a summary report that explains how the submitted evidence supports the product’s recommended conditions of use.
Although the published Class III service standard is 210 calendar days, applicants should not assume that an NPN will be issued within these seven months. The standard is not a guaranteed approval timeline, and Health Canada has acknowledged that the volume of prioritized applications awaiting review exceeds its current review capacity.
For practical launch planning, SNI recommends allowing approximately one year for most Class III applications, particularly where the submission is scientifically complex or may require a response to an IRN.
How Does Health Canada Prioritize NPN Applications?
Health Canada’s NHP Workload-Management Approach
Health Canada’s recent workload-management approach is intended to focus review resources on NHPs that will be manufactured and/or imported in Canada within the next twelve (12) months.
PLA Attestation and Site Licence Information
Applicants intending to manufacture and/or import their product in Canada within the next twelve (12) months should accurately complete the applicable workload-management attestations on the PLA. Where a Canadian-based NHP site licence holder will manufacture, package, label, or import the product, applicants should also identify the relevant site and provide its active site licence number.
Accurately completing this section is important because eligible applications may be prioritized based on whether the product will be manufactured and/or imported in Canada within the next twelve (12) months, including where the application will:
- Be imported into Canada within the next twelve (12) months
- Be manufactured in Canada within the next twelve (12) months
- Support an existing product already marketed in Canada
Applications that do not include the required workload-management information may be deprioritized and reviewed only as Health Canada’s resources permit.
Canadian Site Information and Review Queue Positioning
At a recent industry conference with Health Canada, the Directorate also indicated that it intends to give further priority to applications identifying a Canadian site with an active NHP site licence number.
For applicants using a Canadian manufacturer, packager, labeller, or importer, confirming the site’s licensing status early and accurately listing the active site licence information may therefore support stronger positioning within Health Canada’s review queue.
This does not guarantee that the application will be reviewed or approved within a specific period. However, it gives Health Canada clearer evidence that the product is connected to legitimate Canadian manufacturing and/or importation activity in the near term.
What Happens After an NPN Application Is Submitted?
Health Canada reviews NHP applications in three main stages:
Administrative Screening
Health Canada first checks that the application is complete and properly filed. Errors such as missing documents, incorrect forms, or inconsistent information can lead to delays or refusal without an IRN.
Regulatory Screening
Applications that pass administrative screening are reviewed against regulations, monographs, and the submitted PLA information. Class I and II applications typically receive the directorate’s decisions at this stage, while Class III applications move to further assessment.
Class III Assessment
For Class III applications, Health Canada evaluates whether the submitted evidence supports the product’s safety, efficacy, and proposed conditions of use. Clear, well-organized evidence can help streamline this review.
Information Request Notices (IRNs)
Health Canada may issue an IRN if additional product information is needed for review. Applicants typically have 5 to 15 days to respond to the issued request.
Incomplete or inadequate responses may result in further information requests or application refusal. Given the short response windows, applicants should be prepared to respond promptly and comprehensively, addressing each item in the IRN and providing all requested information. Failure to respond by the deadline, or to resolve the identified deficiencies, may ultimately result in refusal.
How Can Brands Reduce the NHP Review Timeline?
No regulatory strategy can guarantee that Health Canada will issue an NPN by a specific date. However, brands can reduce avoidable delays, improve submission quality, and support stronger positioning within Health Canada’s review queue by:
- Confirming the product classification and application class before developing the submission strategy
- Using monograph-aligned ingredients, doses, directions, and claims where they support the commercial objective
- Ensuring the evidence directly supports the proposed conditions of use, including population, dose, duration, route of administration, and claims
- Aligning the PLA, quality documentation, evidence package, and Canadian label before filing
- Accurately disclosing whether the product will be manufactured and/or imported in Canada within the next twelve (12) months
- Confirming and listing an active Canadian NHP site licence number where a Canadian manufacturer, packager, labeller, or importer is involved
- Preparing internal regulatory, scientific, and quality teams to respond quickly and completely to Health Canada correspondence
For complex products, timeline management should begin well before the intended Canadian launch date. Brands should not wait until inventory has been manufactured, retail commitments have been finalized, or importation plans are already in motion before confirming the licensing pathway.
Final Remarks
NPN timelines should be treated as a core commercialization planning issue, not a final administrative step. While Health Canada’s service standards provide a useful starting point, the practical timeline for approval depends on the product’s classification, the strength and organization of the evidence package, the completeness of the PLA, and whether the application is positioned appropriately within current workload-management priorities.
For brands preparing to enter or expand in the Canadian market, the strongest strategy is to confirm the regulatory pathway early, align all submission materials before filing, and build realistic review timelines into launch planning. This is especially important for Class III products, where scientific assessment, potential IRNs, and current review backlogs can significantly affect timing.
A well-prepared NPN application cannot guarantee a specific approval date, but it can reduce avoidable delays, improve regulatory clarity, and support a more predictable path to market.
Plan the NPN Pathway Before Setting the Launch Date
The time required to obtain an NPN depends on both the regulatory complexity of the product and the quality of the application. Confirming the pathway early, supporting the proposed claims, verifying ingredient details, and aligning the PLA with the quality documentation and label can reduce avoidable delays and support more realistic commercial planning.
SNI helps NHP brands navigate product classification, regulatory strategy, evidence review, PLA preparation, workload-management planning, Health Canada responses, and compliant label development. By aligning these workstreams early, brands can reduce rework and move toward the Canadian market with greater control and confidence.
With more than 2,100 successful NHP applications, over 20 years of industry consulting experience, and a multidisciplinary team, SNI streamlines NHP licensing, quality, and compliance. Connect with our team to learn more about our product and site licensing solutions and strategic market-entry support.
Book an introductory call using the following form:
FAQ
Can a brand sell an NHP while its NPN application is under review?
No. Submitting a PLA does not authorize an NHP for sale in Canada. Before the product can be sold, Health Canada must issue an NPN or DIN-HM and the applicant must provide complete site information for each applicable manufacturer, packager, labeller, importer, distributor, and storage facility.
How long should a Class III NPN application take?
Health Canada’s published service standard for a Class III application is 210 calendar days. However, this is not a guaranteed approval timeline. Based on current application volumes and SNI’s experience with the existing Health Canada backlog, applicants should consider allowing approximately one year for practical commercialization planning, particularly for complex applications or submissions that may require additional information.
Can Workload-Management Information affect NPN application priority?
Yes. Applicants must accurately confirm whether the product will be sold or manufactured in Canada within (twelve) 12 months of receiving authorization. For eligible applications received on or after December 15, 2025, the review order is based on the application’s date of receipt. Eligibility and review order do not guarantee that Health Canada will issue a regulatory decision within the applicable service standard.
How can applicants reduce avoidable NPN application delays?
Applicants can reduce avoidable delays by submitting a complete and internally consistent PLA supported by evidence that directly reflects the product’s ingredients, claims, dose, target population, duration of use, and route of administration. The application should align with the evidence package, quality documentation, site information, and Canadian label. For Class III applications, a structured summary report should clearly connect the evidence to the proposed conditions of use.
Should a brand set its Canadian launch date before receiving an NPN?
A brand may establish a provisional launch plan, but it should avoid committing to a firm Canadian sale date until the NPN or DIN-HM has been issued and all required site information has been provided to Health Canada. Class III commercialization plans should account for a potentially extended review period, as well as the possibility of an IRN, label revisions, or changes to the proposed conditions of use.
